Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Gross Profit (2016 - 2025)

Historic Gross Profit for Corcept Therapeutics (CORT) over the last 10 years, with Q3 2025 value amounting to $203.0 million.

  • Corcept Therapeutics' Gross Profit rose 1300.26% to $203.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $727.8 million, marking a year-over-year increase of 1762.13%. This contributed to the annual value of $664.2 million for FY2024, which is 3956.01% up from last year.
  • According to the latest figures from Q3 2025, Corcept Therapeutics' Gross Profit is $203.0 million, which was up 1300.26% from $191.0 million recorded in Q2 2025.
  • Corcept Therapeutics' Gross Profit's 5-year high stood at $203.0 million during Q3 2025, with a 5-year trough of $78.2 million in Q1 2021.
  • Its 5-year average for Gross Profit is $128.7 million, with a median of $116.1 million in 2023.
  • Its Gross Profit has fluctuated over the past 5 years, first plummeted by 1444.69% in 2021, then surged by 4733.1% in 2024.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Gross Profit stood at $97.5 million in 2021, then increased by 4.21% to $101.6 million in 2022, then soared by 31.46% to $133.5 million in 2023, then skyrocketed by 34.0% to $178.9 million in 2024, then increased by 13.47% to $203.0 million in 2025.
  • Its Gross Profit was $203.0 million in Q3 2025, compared to $191.0 million in Q2 2025 and $154.8 million in Q1 2025.